3^rd International Meeting & Expo on
Medicinal Chemistry and Pharmaceutical Science

Dr. Pawan Saharan, with a vision to provide Health for all, Invented World’s 1st Immunity Enhancement Drug to treat HIV and host of other Immunity problems via Broad Spectrum Antiviral and New Generation Immuno-modulator- RECEPTOL®. Prestigious Who’s Who American Historical Society (Boston) nominated Dr. Saharan as a World.Leader in healthcare industry responsible for changing the destiny of nations & human race via the creative contribution in the healthcare sector via Receptol that builds body’s own immune system, providing hope to most disenchanted terminally ill patients globally. He has global experience in running healthcare industry, including the Pharmaceuticals MNCs and hospitals at the top management level in India & USA.He created the first truly Nano-Bio-IT Helix via inventing Radha 108 Nano-Peptides for AIDS therapy : RECEPTOL® along with reusable micro-chip diagnostics for AIDS, Cancer, TB and other infections, costing a fraction of current tests creating a paradigm shift in healthcare & bringing smile on Billion Faces who could not afford modern treatment.

Dr. Saharan created the first truly Nano-Bio-IT Helix via inventing Radha 108 Nano-Peptides for AIDS therapy : RECEPTOL® along with reusable micro-chip diagnostics for AIDS, Cancer, TB and other infections, costing a fraction of current tests creating a paradigm shift in healthcare & bringing smile on Billion Faces who could not afford modern treatment.

Mircea Ciuca, MD is currently Global Head of Medical & Clinical Drug Safety at Vifor Pharma in Switzerland. He is leading a team of scientists and physicians involved in all aspects of pharmacovigilance, in both development and post-marketing settings. Mr. Ciuca has about 13 years of experience in drug safety. Prior to join Vifor Pharma he held various positions (Deputy QPPV, Senior Pharmacovigilance Medical Manager, Drug Safety Advisor) at large pharmaceutical companies in The Netherlands, after successfully establishing and leading the medical- scientific department of a medium-size CRO in Rotterdam.

Clinical Drug Safety, clinical practice, Pharmacovigilance

He is the director of the Horváth Csaba Laboratory of Bioseparation Sciences and holds the MTA-PE Lendulet Professorship in Translational Glycomics at the University of Pannonia (Hungary). His work focuses on glycomics and glycoproteomics investigation using capillary electrophoresis and CESI-MS for biomedical, cell biology, and biopharmaceutical purposes. More than 290 scientific articles, 35 book chapters, 4 textbooks, and 23 patents have all been written by Professor Guttman. He is a member of the Hungarian Academy of Sciences, serves on the boards of various international organizations, and is a member of a dozen editorial boards for scholarly periodicals.

His research interests include the glycomics and glycoproteomics analysis of biomedical, cell biology, and biopharmaceutical.

Cecil Nick has a degree in biochemistry and has worked in regulatory affairs for over 30 years, with a focus on the clinical development of biological and biotech goods. supported approximately 80 discussions with biosimilar agencies in the EU, US, Canada, and RoW and 7 marketing approvals for biosimilar products. specializes in providing clients with broad knowledge, notably in the areas of biosimilars, comparability, clinical research, orphan pharmaceuticals, and training. Fellow of TOPRA, guest lecturer in the MSc Clinical Research and MSc Pharmaceutical Sciences programs at Greenwich University, and biotech module leader for the TOPRA MSc program. He was on SCRIP Clinical Research's editorial board.

Clinical development of biological and biotech products

David KREHER is an Associate Professor of Chemistry at UPMC. He earned his Ph.D. in organic and materials chemistry from the Universities of Angers (France) and Zaragoza (Spain) in 2001. His research project lasted 4 years and was funded by the CNRS (National Center of Scientific Research). It also included 1 year of studies and formation (HPLC, MS, RPE) in Zaragoza and Barcelona.

2D-3D self-assembled systems, organic chemistry, electrochemistry, optoelectronic materials, organic emissive materials. The current search includes design, synthesis, and studies of (macro) molecular materials for organic electronics, and pyridazine biphasic fluo / phosphorescent transmitters.

At the age of 25, Dipti Gulati earned her Ph.D. from Allahabad University. She then pursued postdoctoral research on protein-carbohydrate interactions at the Indian Institute of Sciences in India and the Albert Einstein College of Medicine in the United States. She currently serves as the president of the consulting firm PJI Biotech. In Amgen, BioMerieux, Emergent Bio Solutions, Diosynth, and SmithKline Beecham Pharmaceuticals in the past, she held a variety of management positions. She is a Committee Member for numerous PDA organizations and has more than 25 publications published in reputable journals.

Biologics and Biosimilars

Dr. Kamali Chance serves as vice president and director of the Biosimilars Center of Excellence's global regulatory strategy for biosimilars. She has worked in the healthcare sector for more than 25 years, the last 17 of which she spent in regulatory relations and regulatory planning. The FDA and EMA have worked with Dr. Chance in the past. She offers guidance to biotechnology and pharmaceutical businesses as they establish regionally tailored and/or global regulatory strategies for the creation of biosimilar goods. Dr. Chance has written or co-written several articles on the creation of biosimilars. She holds a Ph.D. in Nutrition/Nutritional Biochemistry, a Master's degree in Public Health, and a certification in Regulatory Affairs.

Regulatory strategy for several biosimilar products currently in development including biosimilars of Enbrel, Remicade, Herceptin, Rituxin/Mabthera, Humira, Avastin, Erbitux, Epogen, Insulins, Forteo and Neupogen/Neulasta.

The recent completion of Captain Brouker's outstanding 30-year naval service. He started his naval career as the department head of several hospital pharmacies in the US, abroad, and on ships. He held the positions of Commanding Officer at one of the biggest naval hospitals in the world and Executive Officer at a military hospital abroad. Also, Captain Brouker held the position of Chief of Staff for Naval Medicine West, where he oversaw the care of 700,000 patients at 10 hospitals from the Indian Ocean to the West Coast. He worked with 10 Commanding Officers in this capacity, offering daily mentorship and executive coaching.

Pharmacy and Healthcare

At Vifor Pharma in Switzerland, Mircea Ciuca, MD, is the current global head of medical and clinical drug safety. He is in charge of a group of scientists and doctors working on all facets of pharmacovigilance in both pre-and post-marketing environments. In terms of drug safety, Mr. Ciuca has around 13 years of experience. After successfully establishing and overseeing the medical-scientific department of a medium-sized CRO in Rotterdam, he held several positions (Deputy QPPV, Senior Pharmacovigilance Medical Manager, Drug Safety Advisor) at large pharmaceutical companies in The Netherlands before joining Vifor Pharma.

Clinical Drug Safety, clinical practice, Pharmacovigilance

Dr. Adel has worked for Memorial Sloan-Kettering Cancer Center for the past 12 years in the roles of director of the oncology residency program and manager of clinical pharmacy services. Dr. Adel received her PharmD from the Lebanese American University School of Pharmacy in Byblos, Lebanon. At the American University of Beirut, she earned her first undergraduate degree, a bachelor of science in geology. Dr. Adel relocated to the US after completing her PharmD and underwent postgraduate studies at St. Jude Children's Research Hospital via the International Outreach Program. The Johns Hopkins Hospital, where she later worked as a research assistant, was where she then went on to do a pharmacy practice residency (PGY-1) and an oncology specialty residency (PGY-2). Ever since she started working at Sloan-Kettering.

Hematology/Oncology

In the field of biotechnology, Robert Salcedo has more than 25 years of experience. has held executive positions at both Amgen and Genentech. He also served as the leader of a young biosimilar company that created and submitted numerous applications in the US and the EU. He is a co-founder of BiosciencesCorp and Biosimilar Solutions, businesses devoted to assisting biotech and biosimilar businesses in the development of their business plans and the commercialization of their products. Robert frequently produces succinct, impactful essays that are posted as part of his LinkedIn profile.

Biotechnology and Solid Dose Manufacturing

Tirasak earned his Ph.D. from the Mahidol University Faculty of Microbiology in Bangkok, Thailand. He received his postdoctoral training at Temple University's NeuroVirology and Cancer Biology Center in Philadelphia. He is currently a full professor of microbiology and immunology at Rangsit University in Thailand's graduate program in medical technology. In addition to music and athletics, he is interested in a variety of academic disciplines in the liberal arts and sciences. His research primarily focuses on the interactions between viruses and cells, as well as bacteriophage and viral illnesses in invertebrate animals. His study, however, also covers autoimmune disorders, cancer biology, and the connection between MHC molecules and a few particular diseases and viral vaccinations.

Viral and cellular interaction, bacteriophage, viral diseases, viral vaccines, autoimmune disease, and cancer biology including the relationship of MHC molecules to some specific diseases and viral vaccines

Dr. Osman Adiguzel graduated from the Department of Physics, Ankara University, Turkey in 1974 and received Ph.D.- degree from Dicle University, Diyarbakir-Turkey. He studied at Surrey University, Guildford, UK, as a post-doctoral research scientist from 1986-1987, and his studies focused on shape memory alloys. He worked as a research assistant, from 1975-80, at Dicle University and shifted to Firat University in 1980. He became a professor in 1996, and he retired due to the age limit of 67, following academic life of 45 years. He published over 80 papers in international and national journals; He joined over 120 conferences and symposia at the international and national level as Plenary Speaker, Keynote Speaker, Invited speaker, speaker, or Poster presenter. He served as the program chair or conference chair/co-chair in some of these activities. In particular, he joined in the last six years (2014 - 2019) over 60 conferences as Speaker, Keynote Speaker, and Conference Co-Chair organized by different companies in different countries. Additionally, he retired at the end of November 2019, and contributed with Keynote/Plenary Speeches at over 60 Virtual/Webinar Conferences, due to the coronavirus outbreak two years of his retirement, in 2020 and 2021. Dr. Adiguzel served as his directorate of the Graduate School of Natural and Applied Sciences, Firat University from 1999-2004. He supervised 5 Ph.D.- theses and 3 M. Sc theses. He is also a technical committee member of many conferences. He received a certificate which is being awarded to him and his experimental group in recognition of the significant contribution of 2 patterns to the Powder Diffraction File – Release 2000. The ICDD (International Centre for Diffraction Data) also appreciates the cooperation of his group and interest in the Powder Diffraction File.

Shape memory effect and displacive phase transformations in shape memory alloys and other alloys, molecular dynamics simulations, alloy modeling, electron microscopy, electron diffraction, x-ray diffraction, and crystallography.

Julie received her BSc(Hons) in Chemistry from University College Cork in 2004, then began her career as a Senior QC Analyst at Pfizer. She subsequently worked for an electrochemical start-up "Anzode" in New Zealand and as an analytical chemist for Colorcon before moving into investment banking, where she used her experience managing projects to perform Execution Management at CIBC for 5 years. Julie then returned to science, obtaining an MSc in Drug Design from University College London, where she earned the Dean's Prize for her dissertation on repositioning drugs to treat malaria. She became a member of the OICR Drug Discovery team in 2017, working as a computational chemist, specifically virtual screening, providing structural insights to binding, generating homology models of proteins as well as database management for various projects. Julie has been working as a Senior Scientist on the Drug Discovery team at Cyclica since August, 2020, where she applies Cyclica's technology to drug discovery projects. Today's talk will provide an overview of Cyclica's MatchMaker technology and how Julie used Matchmaker to design a novel inhibitor for DCAF1, resulting in the first co-crystal structure of DCAF1 with a ligand to be deposited in the PDB.

Drug Discovery

Dr. Kouros Motamed, Ph.D. has been the Director of Drug Development at NantBioScience, Inc. since April 2016. Prior to that, he has served as VP of Strategic Alliances and Clinical Communications and VP of Clinical Development and Nanomedicine at Sorrento Therapeutics from 2013 to 2016. He has also served as a co-founder and CSO/CTO of Igdrasol, Inc. and Biomiga Diagnostics start-up companies from 2011-2013. Prior to that, Dr. Motamed served as the MOA and Molecular Biology Group Head at Celgene Corp. and Abraxis BioScience Inc. from 2007-2011. Dr. Motamed held an Assistant Professorship position in the Department of Pathology and Vascular Biology Center at Georgia Health Sciences University from 2002-2007. He has over 30 original publications in peer-reviewed journals, over 50 conference presentations and has 5 issued patents. He has served on the Editorial Board of Journal of Nanomaterials & Molecular Nanotechnology since 2013. Dr. Motamed received a B.S. degree in Biology from University of San Francisco and a Ph.D. degree from the University of California, Davis in Microbiology.

Drug Discovery,Development Angiogenesis,Tumorigenesis, Tumor Microenvironment Normalization Clinical Biomarker, Companion Diagnostic Development Point-of-Care Diagnostics Clinical Development of Personalized Nanomedicines in Solid Tumors

Henrique Faneca is principal investigator at Centre for Neuroscience and Cell Biology, and invited assistant professor at University of Coimbra. He received his Ph.D. degree in Biochemistry from Coimbra University in 2005. The main focus of his research is the development of lipid- and polymeric-based nanosystems for gene and drug delivery into target cells and the generation of new antitumor strategies, involving different gene therapy approaches either per se or in combination with chemotherapeutic agents. Henrique Faneca is author of more than 45 scientific papers corresponding to over 1500 citations and to an h-index of 19.

Nanosystems for drug and gene delivery; Gene Delivery; Drug Delivery; Cancer Gene Therapy; Cancer Therapy

Professor Puzyn is the author of over 70 scientific articles in leading journals (eg. Nature Nanotechnology). His work has been cited more than 1,000 times and the Hirsch index is 21. Professor Puzyn is an active member of the international emvironment involved in the issues of chemical safety and nanotechnology: as the leader of two international projects thanks to the EU 7th Framework Programme (NanoBRIDGES and NanoPUZZLES), initiatives under the European Nanosafety Cluster and as a member of the Steering Committee of the MODENA Action, implemented within the framework of COST - European Cooperation in Science and Technology. He is also the winner of many prestigious national and international awards, i.e.: individual scholarship of the Japanese Association for the Promotion of Science, grants of the Foundation for Polish Science (programmes: START, HOMING and FOCUS), a scholarship of the Ministry of Science and Higher Education holder and the winner of the Polish Prime Minister Prize for the best habilitation thesis in 2012.

Computational methods for designing nanomaterials

Ziyad S. Haidar is an Associate Professor of Biomaterials and Tissue Engineering and the Scientific Director of the Centro de Investigación en Biología y Regeneración Oral (CIBRO), Centro de Investigación Biomédica (CIB), Facultad de Odontología, Universidad de los Andes in Santiago de Chile. Concurrently, Prof. Dr. Haidar is the Founder and Head of the Biomaterials, Pharmaceutical Delivery and Cranio-Maxillo-Facial Tissue Engineering Laboratory (BioMat'X) and Faculty member in the PhD program (BioMedicine) at the Facultad de Medicina, Universidad de los Andes in Santiago de Chile. Haidar is an oral and maxillofacial surgeon with a PhD in biomaterials and tissue engineering from McGill University, Montréal , Canada; and post-doctoral training at the Montréal Shriners Hospital, McGill University Health Center, Montréal , Canada. Before moving to Chile, he served as the Chair of Excellence in BioEngineering at the Université de Limoges, Limoges, France and was an Assistant Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA. Haidar has won several prestigious awards from the International Bone and Mineral Society, Society for Biomaterials, Canadian Biomaterial Society and Canadian/Lebanese Society of Plastic Surgeons, to name a few. He has more than 80 publications, conference proceedings, text-books and patents and is an editorial board member of several national and international scientific journals and periodicals.

Patient-oriented application of bionanotechnology; Biopolymers; Bioceramics and Drug delivery systems for the repair; Restoration and replacement of challenging craniofacial and orthopaedic defects.